Mesenchymal Cell News Volume 7.03 | Jan 27 2015

DNA Methyltransferase Inhibition Accelerates the Immunomodulation and Migration of Human Mesenchymal Stem Cells
Researchers treated human mesenchymal stem cells with 5-azacytidine, a DNA methyltransferase inhibitor, and confirmed that the inhibitory effects on mononuclear cell proliferation and cell migration toward activated T cells were increased. [Sci Rep] Full Article

Engineered Adenoviruses Combine Enhanced Oncolysis with Improved Virus Production by Mesenchymal Stromal Carrier Cells
Scientists show that an Ad5/3 chimeric oncolytic adenovirus capsid, containing the adenovirus serotype 3 cell-binding domain, strongly increases the entry into human bone marrow-derived mesenchymal stromal cells and into established and primary pancreatic cancer cells. [Int J Cancer] Abstract

Bone Marrow Stromal Mesenchymal Cells Induce Down Regulation of CD20 Expression on B-CLL: Implications for Rituximab Resistance in CLL
Researchers investigated whether mesenchymal stromal cells (MSC) may regulate the CD20 expression on chronic lymphocytic leukemia (B-CLL). For this purpose, B cells from CLL patients were isolated and co-cultured on MSC. B-CLL cells were collected from B-CLL/MSC co-cultures and examined for their expression of CD20. [Br J Haematol] Abstract

Evaluation of the Therapeutic Effects of Conditioned Media from Mesenchymal Stem Cells in a Rat Bisphosphonate-Related Osteonecrosis of the Jaw-Like Model
Scientists showed that mesenchymal stem cell (MSC)-conditioned media (CM) has protected rat MSCs and rat osteoclasts. MSC-CM enhanced the expression of osteogenic-related genes and neovascularization-related genes by real-time reverse-transcriptase polymerase chain reaction analysis in in vitro study. [Bone] Abstract

Growth Factor and Ultrasound-Assisted Bioreactor Synergism for Human Mesenchymal Stem Cell Chondrogenesis
Scientists hypothesized that a combination of ultrasound at 5.0 MHz and transforming growth factor-β3 induces human mesenchymal stem cell differentiation to chondrocytes. [J Tissue Eng] Full Article

MicroRNAs-141 and 200a Regulate the SVCT2 Transporter in Bone Marrow Stromal Cells
The authors investigated the impact of microRNA (miR)-141 and miR-200a on sodium dependent vitamin C transporter 2 (SVCT2) expression. They found that mouse bone marrow stromal cells expressed miR-141 and miR-200a and repressed SVCT2 expression at the functional level by targeting the 3′-untranslated region of mRNA. [Mol Cell Endocrinol] Abstract

Persistent DNA Damage-Induced Premature Senescence Alters the Functional Features of Human Bone Marrow Mesenchymal Stem Cells
Researchers investigated the response of human bone marrow mesenchymal stem cells to the genotoxic agent actinomycin D, a well-known anti-tumor drug. [J Cell Mol Med] Abstract

Neuroprotective Effects of Intravitreally Transplanted Adipose Tissue and Bone Marrow-Derived Mesenchymal Stem Cells in an Experimental Ocular Hypertension Model
Scientists investigated the neuroprotective effects of bone marrow bone marrow-derived and adipose tissue-derived mesenchymal stromal cells that were intravitreally transplanted in an experimental ocular hypertension model. [Cytotherapy] Abstract

The Role of Reactive Oxygen Species in Mesenchymal Stem Cell Adipogenic and Osteogenic Differentiation: A Review
The authors provide a detailed overview of the influence of reactive oxygen species on adipogenic and osteogenic differentiation in mesenchymal stromal cells. [Stem Cells Dev] Abstract

Visit our reviews page to see a complete list of reviews in the mesenchymal cell research field.

BioTime Announces Issuance of 14 New Patents in the Fields of Regenerative Medicine, Stem Cell Technology, and Cancer Therapy
BioTime, Inc. announced the issuance of 14 new patents covering a wide range of the core technologies of BioTime and its subsidiaries Asterias Biotherapeutics, Inc., OrthoCyte Corporation, ES Cell International Pte Ltd, OncoCyte Corporation, and ReCyte Therapeutics, Inc. [BioTime, Inc.] Press Release

From our sponsor: Learn about assays for cord blood. Download the free technical bulletin.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mesenchymal cell community.

NEW Postdoctoral Researcher – Therapy of Malignant Hematologic Diseases (University of Crete)

NEW Postdoctoral Research Assistant – Mesenchymal Stem Cell Epigenetics (University of Oxford)

Director (California Institute for Regenerative Medicine)

Postdoctoral Fellow – Wnt Signaling in Development and Disease (Van Andel Research Institute)

Postdoctoral Fellowship – CNS Inflammation (Rutgers University)

Postdoctoral Position – Morphogenetic Signaling Pathways in Development and Disease (University of Rochester Medical Center)

Postdoctoral Position – Epigenetic Regulation of Cell Fate and Metabolism (University Medical Center Freiburg)

Scientist – Myogenic Progenitor Cell Biology (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.